Cough Hypersensitivity Syndrome Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄











  • 市場概況
  • 市場驅動力
    • 擴大目標人群
    • 強大的渠道和新療法的引進
    • 加強政府舉措
  • 市場限制
    • 藥物濫用和依賴性
  • 波特的五力分析


  • 按毒品類別
    • 鎮咳藥
    • 吸入皮質類固醇(ICS)
    • 短效beta 2激動劑(SABA)
    • 抗膽鹼藥
    • 抗組胺藥
    • 質子泵抑製劑
    • 其他
  • 最終用戶
    • 醫院內藥房
    • 零售藥房
    • 在線藥房
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東/非洲
    • 南美洲


  • 公司簡介
    • Astrazeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline PLC
    • Johnson & Johnson Inc.
    • Merck & Co. Inc.
    • Novartis International AG
    • Pfizer Inc.
    • Teva Canada Limited
    • Vertex Pharmaceuticals Incorporated

第7章 市場機會與將來動向

Product Code: 68851

The cough hypersensitivity syndrome treatment market is expected to register a CAGR of 5.5% over the forecast period. The market is projected to register moderate growth over the forecast period, which can be attributed to factors, such as humid climate, unhealthy lifestyle, and rising incidence of diseases.

Cough is a common disease affecting millions of people worldwide. The rise in the prevalence of chronic respiratory diseases globally is leading to an increase in chronic cough conditions globally. Thus, the growing burden of disease offers a promising future for the global market. Although some studies suggest that the risk of developing cough may be increased, due to other certain factors, such as asthma, smoking, hot and humid climate, and viral or bacterial infection.

As per the WHO, cough is ranked as the most prevalent disease globally. Most of the novel products are reformulated drugs with improvised vehicles or combinatorial therapies. The treatment algorithm is witnessing a paradigm shift from small molecules towards natural therapies and biologics. Combination therapies have also been gaining popularity over the last few years. Most industry-sponsored products are in clinical trials.

In addition, the key players are focusing on making cough syrup of pleasant taste and easy intake for oral use. The growing disease burden includes majority of pediatric population as they have lower immunity level compared to adults. Most pediatric patients prefer liquid as dosage forms. Growing demand of cough remedies is driven by the presence of routinely monitored formulations, technological advancement in the field of drug delivery systems, and increasing awareness amongst patients. However, drug abuse and dependence on cough hypersensitivity syndrome drugs are the factors that are expected to restrict the market's growth.

Key Market Trends

The Retail Pharmacy From Distribution Channel Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

  • The retail pharmacy segment dominated the market, owing to due to easy availability and accessibility of these pharmacies. For instance, MedPlus has around 1650 outlets out of which 1,350 are self-owned and rest are taken as a franchisee. Retailers provide discounts on bulk purchases, offer quick delivery, and always have sufficient product stock, owing to which consumers opt for these distribution channels.
  • Moreover, online pharmacy is estimated to be the fastest-growing segment over the forecast period. The convenience of delivering the medicines at the doorstep is the major advantage of online pharmacy. The discounted price that the online pharmacies provide is also a factor that drives the growth of the market. As per an estimate, there are between 30,000 and 50,000 online pharmacies operating in the United States, making online pharmacies a leading segment.

The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America holds the highest share, owing to the presence of major market players. Several collaborative efforts were undertaken by major companies to enhance their R&D capabilities and ensure high medical standards are anticipated to impel the demand across this region. Moreover, the majority share can also be attributed to the high disease burden in this region. Increasing cases of cough and rising pediatric population are the key factors that are driving the market studied in this region.

The Asia-Pacific region is expected to witness the fastest growth over the forecast period. Strategic partnerships between pharmaceutical companies and government organizations are on a rise in the region, particularly to develop generic drugs and spread awareness amongst healthcare professionals. Increasing awareness levels and rising focus of healthcare providers on the eradication of coughing ailments are expected to boost growth within the region. This factor is expected to boost the growth of the APAC market.

Competitive Landscape

The market for cough hypersensitivity syndrome treatment is highly competitive and consists of several global as well as local players. Investment for the development of effective and long-acting products with lesser adverse effects and improving geographic penetration through partnerships and collaborations are the key strategies adopted by the companies to increase their market share. The major players include Johnson & Johnson, Bayer AG, GlaxoSmithKline plc, Pfizer, Novartis, AstraZeneca, and Teva Canada Limited.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Expanding Target Audience
    • 4.2.2 Robust Pipeline and the Introduction of Novel Therapies
    • 4.2.3 Increasing Government Initiatives
  • 4.3 Market Restraints
    • 4.3.1 Drug Abuse and Dependency
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Class
    • 5.1.1 Antitussive Agents
    • 5.1.2 Inhaled Corticosteroids (ICS)
    • 5.1.3 Short Acting Beta2-Agonists (SABA)
    • 5.1.4 Anti-cholinergics
    • 5.1.5 Antihistamines
    • 5.1.6 Proton Pump Inhibitors
    • 5.1.7 Other Drug Classes
  • 5.2 By End User
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Astrazeneca PLC
    • 6.1.2 Bayer AG
    • 6.1.3 Boehringer Ingelheim GmbH
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Johnson & Johnson Inc.
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Novartis International AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Teva Canada Limited
    • 6.1.10 Vertex Pharmaceuticals Incorporated